Who Owns Collegium Pharmaceutical Company?

Collegium Pharmaceutical Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Collegium Pharmaceutical?

Understanding the ownership structure of a Collegium Pharmaceutical SWOT Analysis is crucial for investors and stakeholders alike. From its inception in 2002 as a specialty pharmaceutical company, Collegium Pharma has navigated a complex landscape of public and private ownership. The company's journey, marked by an IPO in 2015, reveals a fascinating evolution of control and influence.

This analysis delves into Collegium ownership, exploring its major shareholders, the influence of its executive team, and the impact of its strategic decisions. We'll examine the shift from private to public ownership, analyzing the implications for the company's future. Discover the key players shaping the destiny of this drug manufacturer and its impact on the market. This exploration will answer critical questions like: Who is the CEO of Collegium Pharmaceutical? and Who founded Collegium Pharmaceutical?

Collegium Pharmaceutical, a prominent Pharmaceutical company, was established in 2002. The company's early trajectory and ownership structure played a crucial role in its development. Understanding the founders and initial investors provides insight into the company's foundational strategy and early financial backing.

The company's initial phase saw the involvement of experienced entrepreneurs and institutional investors. This combination was critical for navigating the early challenges of the pharmaceutical industry. The early ownership structure set the stage for future growth and strategic decisions.

Michael Heffernan, an experienced entrepreneur in the pharmaceutical and healthcare sectors, founded Collegium Pharmaceutical. He served as the President and Chief Executive Officer from October 2003 to June 2018. His prior experience, including founding Onset Therapeutics, LLC, a dermatology-focused company, was invaluable.

Founding

Collegium Pharmaceutical was founded in 2002 by Michael Heffernan.

Early Leadership

Michael Heffernan served as President and CEO from October 2003 to June 2018.

Institutional Investment

Boston Millennia Partners (BMP) was an early investor.

BMP's Initial Stake

BMP initially held a 30% ownership position in Collegium.

Early Partnerships

BMP worked closely with management to refine strategy and manage risks.

Equity Details

Specific equity splits for founders and early investors are not publicly detailed.

Boston Millennia Partners (BMP) was a key early institutional investor in Collegium Pharma, initially holding a 30% ownership stake. This significant early investment allowed BMP to collaborate closely with the management team. While the precise equity distribution among founders and early investors isn't publicly available, the involvement of experienced individuals like Heffernan, combined with institutional backing from firms like BMP, was pivotal during the company's formative years. Early agreements likely included standard venture capital terms, although specific vesting schedules or buy-sell clauses are not readily available in public records. Understanding the Collegium ownership structure from its inception is crucial for assessing the company's evolution and strategic direction. The early financial backing and leadership set the stage for future growth and operational strategies. As of the most recent financial reports, the company continues to evolve, with its ownership structure reflecting its growth and market position.

Key Takeaways

The founders and early ownership structure of Collegium Pharmaceutical shaped its initial strategy and financial backing.

• Michael Heffernan, the founder, provided crucial leadership.
• Boston Millennia Partners (BMP) was a significant early institutional investor.
• The early structure helped manage business and financing risks.
• Specific equity details for founders and early investors are not publicly available.

Collegium Pharmaceutical SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Collegium Pharmaceutical's ownership structure has been significantly shaped by its initial public offering (IPO) and subsequent strategic actions. The company, a prominent pharmaceutical company, went public in May 2015, with an IPO price of $12 per share. As of June 6, 2025, the share price had risen to $30.20, indicating considerable growth since its market debut. This increase in value has attracted significant investment from institutional investors, altering the company's ownership landscape.

The shift in Collegium Pharma's ownership is evident in the substantial holdings by institutional investors. By May 2025, institutional investors held approximately 117.97% of the shares, with mutual funds accounting for around 84.77%. This indicates a strong institutional interest in the company. Furthermore, insider holdings increased slightly from 2.95% to 3.18% during the same period, reflecting confidence from within the company's leadership.

Major institutional shareholders, as of March 2025, include BlackRock, Inc., holding 17.3% of the shares (5.55 million shares), Eventide Asset Management with 2.64 million shares, and Rubric Capital Management with 2.35 million shares. Vanguard Group Inc. and Pacer Advisors, Inc. also hold significant positions, with 2.3 million and 2.14 million shares, respectively. These large institutional holdings can significantly influence Collegium ownership, impacting company strategy and governance. These investors can influence management decisions and affect stock prices through their trading activities. For further insights, check out the Brief History of Collegium Pharmaceutical.

Key Takeaways on Collegium Pharmaceutical Ownership

The ownership structure of Collegium Pharmaceutical is heavily influenced by institutional investors, reflecting strong market confidence.

• Institutional investors hold a dominant position, with approximately 117.97% of shares as of May 2025.
• Mutual funds are also significant shareholders, holding around 84.77% of the company.
• Strategic acquisitions, like the BioDelivery Sciences International Inc. and Jornay PM acquisitions, have impacted the financial structure.
• The acquisitions were financed through a combination of cash and debt, reflecting the company's financial strategy.

Collegium Pharmaceutical PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of March 17, 2025, the board of directors at Collegium Pharmaceutical, a prominent pharmaceutical company, comprised nine members. The company's founder, Michael Heffernan, held the position of Chairman of the Board until his retirement at the Annual General Meeting (AGM) on May 15, 2025. Gino Santini, previously the Lead Independent Director, succeeded Heffernan as Chairman. Furthermore, Dr. Carlos Paya was nominated to the Board for shareholder approval at the May 15, 2025, AGM.

The current leadership structure includes Vikram Karnani, who became CEO in November 2024, also serving on the board. Colleen Tupper, the CFO since 2021, is another key member. Other board members include John A. Fallon, M.D., John G. Freund, M.D., and Rita Balice-Gordon, Ph. D. This composition reflects a blend of experience and expertise, guiding the strategic direction of Collegium Pharma.

In the absence of specific details regarding dual-class shares or special voting rights in recent filings, Collegium Pharmaceutical likely operates under the standard one-share-one-vote principle. The significant institutional ownership suggests that major shareholders wield considerable voting power in corporate decisions. Recent changes, such as the Chairman transition, indicate ongoing board adjustments and strategic shifts within the company. For more insights, you can explore the Target Market of Collegium Pharmaceutical.

Key Takeaways on Collegium Pharmaceutical's Governance

The board of directors at Collegium Pharmaceutical is composed of experienced professionals. The leadership transitions and board appointments reflect the company's evolving strategic direction. Understanding the board's composition is crucial for assessing Collegium Pharma's future.

• The board has nine members as of March 17, 2025.
• Gino Santini is the current Chairman.
• Vikram Karnani is the CEO, appointed in November 2024.
• The company likely follows a one-share-one-vote structure.

Collegium Pharmaceutical Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Collegium Pharmaceutical has actively managed its ownership structure through share repurchase programs and strategic acquisitions. In January 2024, the company authorized a $150 million share repurchase program, demonstrating its commitment to returning value to shareholders. This program included a $25 million accelerated share repurchase (ASR) agreement with Jefferies LLC, announced on May 12, 2025, with final settlement expected in the third quarter of 2025. The ASR involved an initial delivery of 692,281 shares. After this transaction, $65 million remained under the repurchase program.

In 2024, Collegium Pharma repurchased $60 million in shares, acquiring 1.882 million shares at an average price of $31.88 per share. Beyond share buybacks, the company has expanded its portfolio through acquisitions, most notably the acquisition of BioDelivery Sciences International Inc. in 2022 for $669 million. More recently, in September 2024, Collegium Pharmaceutical acquired Jornay PM from Ironshore Therapeutics Inc. for $525 million, marking its entry into the neuropsychiatry market.

Institutional ownership remains a dominant trend for Collegium ownership. As of May 2025, institutional investors held 117.97% of shares, with mutual funds holding 84.77%. Insider holdings saw a slight increase to 3.18% in May 2025. Major institutional shifts include Pacer Advisors, INC. removing 1,723,415 shares (-80.4%) from their portfolio in Q1 2025, while Rubric Capital Management LP added 1,100,000 shares (+88.0%) in Q4 2024. Leadership changes also occurred, with Vikram Karnani joining as President and CEO in November 2024. The company projects strong growth for 2025, with expected product revenues between $735 million and $750 million, and adjusted EBITDA between $435 million and $450 million. Jornay PM is anticipated to generate over $135 million in net revenue in 2025, serving as a primary growth driver.

Key Ownership Changes

Significant shifts in institutional holdings, including Pacer Advisors, INC. and Rubric Capital Management LP.

Financial Performance Projections

Strong revenue and EBITDA forecasts for 2025, driven by existing products and new acquisitions like Jornay PM.

Strategic Acquisitions

Acquisition of Jornay PM to enter the neuropsychiatry market, indicating expansion and diversification.

Share Repurchase Programs

Ongoing share repurchase programs reflecting confidence in the company's financial health and commitment to shareholder value.

Collegium Pharmaceutical Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs